0001209191-22-014145.txt : 20220301 0001209191-22-014145.hdr.sgml : 20220301 20220301171124 ACCESSION NUMBER: 0001209191-22-014145 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220225 FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meyers James R CENTRAL INDEX KEY: 0001387521 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 22699581 MAIL ADDRESS: STREET 1: GILEAD SCIENCES, INC. STREET 2: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001387521 Meyers James R C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD. BRISBANE CA 94005 1 0 0 0 Common Stock 2022-02-25 4 A 0 12500 0.00 A 35700 D Stock Option (Right to Buy) 5.90 2022-02-25 4 A 0 25000 0.00 A 2032-02-24 Common Stock 25000 25000 D Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Includes 1,667 shares subject to the Reporting Person's November 22, 2019 RSU grant that will vest in one final annual installment on November 22, 2022, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through such date and subject to acceleration as provided in the 2018 EIP. The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. James R. Meyers, by /s/ Ron A. Metzger, Attorney-in-Fact 2022-03-01